Immune checkpoint inhibitor–associated myocarditis Case reports and a review of the literature

Immune checkpoint inhibitors (ICIs) are increasingly recognised to effectuate long-lasting therapeutic responses in solid tumours. However, ICI therapy can also result in various immune-related adverse events, such as ICI-associated myocarditis, a rare but serious complication. The clinical spectrum...

Full description

Saved in:
Bibliographic Details
Published inNetherlands heart journal Vol. 30; no. 6; pp. 295 - 301
Main Authors Osinga, T. E., Oosting, S. F., van der Meer, P., de Boer, R. A., Kuenen, B. C., Rutgers, A., Bergmann, L., Oude Munnink, T. H., Jalving, M., van Kruchten, M.
Format Journal Article
LanguageEnglish
Published Houten Bohn Stafleu van Loghum 01.06.2022
Subjects
Cardiology
Medical Education
Medicine
Medicine & Public Health
Review
Review Article
Cardio-oncology
ICI-associated myocarditis
Immune checkpoint inhibitor
Cardiac biomarkers
Associated myocarditis
Online AccessGet full text

Cover

More Information
Summary:Immune checkpoint inhibitors (ICIs) are increasingly recognised to effectuate long-lasting therapeutic responses in solid tumours. However, ICI therapy can also result in various immune-related adverse events, such as ICI-associated myocarditis, a rare but serious complication. The clinical spectrum is wide and includes asymptomatic patients and patients with fulminant heart failure, making it challenging to diagnose this condition. Furthermore, the optimal diagnostic algorithm and treatment of ICI-associated myocarditis is unknown. In this review, we describe two cases on both ends of the spectrum and discuss the challenges in recognising, diagnosing and treating ICI-associated myocarditis.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1568-5888
1876-6250
DOI:10.1007/s12471-021-01655-7